Neurosciences - Strategic Insights Report (Page 2)

Neurosciences

Breakthrough in Human Neuroscience: Researchers Record Cerebellar Activity Non-Invasively

Investigators at University College London (UCL) have published a groundbreaking study on recording cerebellar activity in humans using wearable optically pumped magnetometers. The research, published in Frontiers in Human Neuroscience, demonstrates the potential of non-invasive magnetoencephalography (MEG) to overcome the limitations of traditional electrophysiological recordings in humans. The study utilized

Neurosciences

Enhanced Adaptability in Anthropoids: A Neuroecological Perspective

Research from the University of Oxford has provided new insights into the enhanced adaptability of anthropoids, including humans, monkeys, and apes. According to a study published in the journal Neuroscience & Biobehavioral Reviews, the development of new areas in the prefrontal cortex is responsible for this adaptability. The study suggests

Chronic pain

Developing Personalised Treatments for Chronic Pain: A Breakthrough in Pain Management

Scientists at Oxford University's EPIONE programme are pioneering a new approach to chronic pain treatment, aiming to develop personalised therapies that can reduce or abolish chronic pain. Chronic pain affects between one-third and one-half of the adult population in the UK, costing health services millions in direct treatment

Artificial neural networks

Reusable Modular Architecture Enables Flexible Cognitive Operations

New research conducted by Princeton University Neuroscience Institute has found that the brain's neural networks can be flexibly reused to perform complex cognitive tasks. The study, led by Timothy J. Buschman, used a delayed match-to-sample with delayed report task to demonstrate that mice reused subspaces of neural activity

Neurosciences

Nocebo Effect Impacts Motor Performance in Half of Studied Cases

Research on the nocebo effect's impact on motor performance has highlighted the significance of negative expectations in athletic and everyday movements. A scoping review of 18 studies, conducted by the Research Centre on Aging, evaluated the methodologies used to induce nocebo effects and their effects on motor outcomes.

Artificial neural networks

New Engineering Study Finds Effective Method for Generating Specific dMRI Images

Researchers at the College of Computer and Information Engineering in Taiyuan, People's Republic of China, have developed a novel method for generating specific diffusion magnetic resonance image (dMRI) images using a variable multi-modal image feature fusion adversarial neural network called RISNet. This method, which was financially supported by

Clinical trials

Breakthrough in Parkinson's Treatment: New Investigational Therapy Showcases Promising Results

Researchers at the University of Wisconsin-Madison, in collaboration with biotechnology company Aspen Neuroscience, have made significant progress in developing a novel cell therapy for Parkinson's disease. The treatment involves growing new brain cells from a patient's own cells, which are then grafted into key areas of

Musicians

Musicians' Brains Respond Differently to Pain Due to Long-Term Training

Music training and long-term practice can reshape the brain's response to pain, researchers have found. A study on 40 musicians and non-musicians showed that musicians experienced less discomfort and had a different brain response to pain than non-musicians. The study's findings suggest that musical training can

Securities law

Securities Lawsuit Filed Against Alto Neuroscience, Inc.

Alto Neuroscience, Inc. (NYSE: ANRO) faced a securities lawsuit following allegations that the company made false statements and concealed the ineffectiveness of its product, ALTO-100, in treating major depressive disorder. The lawsuit focuses on the initial public offering (IPO) conducted on February 2, 2024, and the subsequent stock purchases between

Securities law

Securities Class Action Filed Against Alto Neuroscience, Inc.

Investors who purchased or acquired Alto common stock in the initial public offering conducted on or about February 2, 2024, or between February 2, 2024, and October 22, 2024, may be able to seek compensation for their losses through a federal securities class action lawsuit. Faruqi & Faruqi, LLP, a

Class action lawsuits

Class Action Lawsuit Filed Against Alto Neuroscience, Inc.

Investors who purchased shares of Alto Neuroscience, Inc. during a specific period have been issued a notice to contact The Gross Law Firm regarding possible lead plaintiff appointment in a class action lawsuit. The lawsuit alleges that the company made false and/or misleading statements about its product pipeline, ALTO-100,

Class action lawsuits

Class Action Lawsuit Filed Against Alto Neuroscience Over Misleading Public Statements

Alto Neuroscience, a clinical-stage biopharmaceutical company, has been sued in a class action lawsuit over allegedly misleading public statements regarding its product, ALTO-100, which was being tested as a treatment for patients with major depressive disorder. The lawsuit claims that the company's registration statement, prospectus, and other public

See all